# Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants

**Authors**: Amparo L. Figueroa,[1] Bethany Girard,[1] Darin K Edwards,[1] Arshan Nasir,[1] Kimball Johnson,[2] Steven Hack,[1] Xin Cao,[1] Elizabeth de Windt,[1] Veronica Urdaneta,[1] Frances Priddy,[1] Rituparna Das,[1] David C Montefiori,[3] Spyros Chalkias[1]

**Affiliations**: [1]Moderna, Inc., Cambridge, Massachusetts 02142, USA; [2]CenExel, Decatur, Georgia 30030, USA; [3]Duke University Medical Center, Durham, North Carolina 27710, USA.

**Running title:** Evaluation of JN.1 and KP.2 Vaccines

**Corresponding author**:

Amparo L. Figueroa

Moderna, Inc., 325 Binney Street, Cambridge, MA, USA 02142

Phone: 1-617-335-3762

amparo.figueroa@modernatx.com

**Abstract**

COVID-19 vaccines encoding JN.1 (mRNA-1273.167) and KP.2 (mRNA-1273.712) were approved for the immunization programs for the 2024-2025 season. This ongoing, open-label, phase 3b/4 study evaluated the safety and immunogenicity of mRNA-1273.167 and mRNA-1273.712 against vaccine-matched variants and JN.1-lineage subvariants (KP.3.1.1, XEC, LP.8.1) in adults with previous COVID-19 mRNA vaccination. Each of the two groups independently enrolled 50 participants. Both JN.1 and KP.2 vaccines increased neutralizing antibody responses at Day 29 against vaccine-matched variants, as well as against KP.3.1.1, XEC, and LP.8.1. Reduction in cross-neutralization was observed across all tested subvariants compared with the reference variant JN.1.No safety concerns were identified.

**Keywords**: immunogenicity, SARS-CoV-2, KP.2 vaccine, JN.1 vaccine, mRNA-1273

## Background

The rapid spread and diversification of the SARS-CoV-2 Omicron lineage has given rise to the JN.1 variant, which became globally dominant by early 2024 [1] due to enhanced immune-evasion capabilities conferred by a receptor-binding domain (RBD) mutation, L455S, over its parental lineage BA.2.86 [2]. The JN.1 lineage continues to diversify through stepwise evolution or recombination, with KP.2 having circulated previously, and KP.3.1.1, XEC, and LP.8.1 currently in circulation worldwide [3]. XEC, a lineage derived via recombination of the two JN.1 subvariants, has a global presence [4, 5] and is characterized by 2 new mutations in the N-terminal domain (NTD) of the spike, T22N and F59S, compared with the previously dominant KP.3 [4, 6]. More recently, XEC is increasingly outcompeted by LP.8.1, a subvariant of KP.1.1.3 that contains 9 new spike mutations beyond those present in JN.1 [5, 6] and 6 new spike mutations compared with KP.2 [3]. LP.8.1 has already become dominant in the United States and is increasing in prevalence globally [5, 7]. While LP.8.1 seems to be no more immune-evasive than XEC, it shows enhanced spike-hACE2 engagement, which likely contributes to its increased fitness and gradual variant replacement over XEC [6]. Due to increasing global prevalence, XEC and LP.8.1 have been classified as variants under monitoring by the World Health Organization [3] and account for 76% of sequenced variants (LP.8.1: 55%; XEC: 21%) in the United States as of March 2025 [7].

The antigenic evolution within the SARS-CoV-2 JN.1 lineage led to authorization of monovalent variant formulations of mRNA COVID-19 vaccines (2024-2025 formula), which were updated to encode the JN.1 or KP.2 variant [8, 9]. Preclinical versions of the JN.1- and KP.2-encoding mRNA-1273 vaccines, administered both as a 2-dose primary series in naive mice and as a third (booster)

58 dose in previously immunized mice, were shown to drive neutralization against
59 vaccine-matched variants and to cross-neutralize JN.1 subvariants KP.2, KP.3, and
60 LA.2, as well as XEC evaluated in naïve mice only [10], thus supporting variant
61 selection and updated vaccine approvals. While the JN.1- and KP.2-encoding
62 mRNA-1273 vaccines are expected to remain cross-reactive to newly emerging
63 variants within the JN.1 lineage [5, 10], there are no clinical data available regarding
64 their cross-neutralizing potential.

65 This study was conducted as part of an ongoing phase 3b/4 trial
66 (NCT06585241) which aims to generate human serology data for the assessment of
67 immunogenicity and cross-neutralization of updated variant mRNA-1273 vaccines as
68 new SARS-CoV-2 variants emerge. Here, we evaluated the immunogenicity and
69 cross-neutralization of updated monovalent variant formulations of mRNA-1273
70 vaccines, the JN.1 vaccine (mRNA-1273.167) and the KP.2 vaccine (mRNA-
71 1273.712) against vaccine-matched variants and currently circulating and dominant
72 variants (KP.3.1.1, XEC, LP.8.1) [3, 7] in adults with previous COVID-19 mRNA
73 vaccination; safety was also evaluated.

74 **Methods**

75 *Study Design and Participants*

76 This is an ongoing, open-label, single-arm, phase 3b/4 study evaluating the
77 immunogenicity and safety of monovalent formulations of the mRNA-1273 vaccine
78 encoding the SARS-CoV-2 Omicron variants JN.1 (mRNA-1273.167) and KP.2
79 (mRNA-1273.712). Eligible participants were adults (aged ≥18 years) in the US who
80 had ≥3 previous mRNA COVID-19 vaccinations (≥2 mRNA COVID-19 vaccines and
81 an XBB.1.5-encoding mRNA COVID-19 vaccine received between September 2023
82 and August 2024). Participants received a 0.5-mL dose of a single intramuscular

injection (50 µg) of either mRNA-1273.167 (Subprotocol 1) or mRNA-1273.712 (Subprotocol 2) and were followed for 1 month after immunization. Adults with a known history of SARS-CoV-2 infection within 3 months before enrollment were excluded (**Supplementary Appendix**). The study is being conducted in accordance with the Declaration of Helsinki and Council for International Organizations of Medical Sciences international ethical guidelines, applicable International Council for Harmonisation good clinical practice guidelines, and applicable laws and regulations. The protocol, informed consent form, and other relevant documents were reviewed and approved by the institutional review board/independent ethics committee before study initiation. Informed consent was obtained prior to each participant's enrollment into the study.

*Study Vaccines*

The mRNA-1273.167 vaccine (Spikevax, Moderna, Inc.) contains 50 µg of mRNA encoding the full-length SARS-CoV-2 spike protein of the JN.1 variant with 2 proline residue substitutions to stabilize the spike protein into a prefusion conformation. The mRNA-1273.712 vaccine contains 50 µg of mRNA encoding the prefusion-stabilized spike protein of the KP.2 variant.

*Immunogenicity and Safety Assessments*

Sera for assessments of neutralizing antibody (nAb) responses were collected before the variant vaccine was administered (Day 1) and 4 weeks after immunization (Day 29). The nAb titers against vaccine-matched variants (JN.1, KP.2) and JN.1 subvariants (KP.3.1.1, XEC, LP.8.1) were quantified using a lentivirus-based SARS-CoV-2 pseudovirus neutralization assay (Duke University), described previously [11]. Safety assessments included adverse events (AEs) leading to study withdrawal,

107 serious adverse events (SAEs), and AEs of special interest (AESIs) from Day 1
108 through the end of the study.

109 *Statistical Analysis*

110 Immunogenicity was evaluated in the per-protocol immunogenicity set (PPIS)
111 which comprised all participants who received a planned study vaccine, had a
112 negative reverse transcriptase polymerase chain reaction (RT-PCR) test at Days 1
113 and 29, and no major protocol deviations that impacted the key data. The geometric
114 mean (GM) titer and GM fold rise (GMFR) of nAb at Day 29 relative to baseline, with
115 corresponding 95% confidence intervals, were evaluated as a primary endpoint.
116 Safety was assessed in the safety set (all enrolled participants who received study
117 intervention). No statistical hypothesis testing was performed; a descriptive summary
118 of the primary immunogenicity objective was provided.

119 **Results**

120 Overall, 50 participants were independently enrolled in each subprotocol and
121 received mRNA-1273.167 (Subprotocol 1; median age, 63 years; 62% female; 86%
122 Black/African American) or mRNA-1273.712 (Subprotocol 2; median age, 54 years;
123 66% female; 70% Black/African American). The median time on study was 30 days
124 for the mRNA-1273.167 cohort and 29 days for the mRNA-1273.712 cohort. Prior
125 COVID-19 vaccines were categorized into 2, 3, 4, and ≥5 doses, with most
126 participants having received 3 doses (Subprotocol 1: 80%; Subprotocol 2: 76%); the
127 median time (interquartile range [IQR]) since last dose was 310 days (303-316) for
128 the mRNA-1273.167 cohort and 330 days (277-338) for the mRNA-1273.712 cohort.
129 Prior COVID-19 vaccination included an original mRNA monovalent formulation
130 (mRNA-1273 or BNT162b2; mRNA-1273.167, 100% recipients; mRNA-1273.712,
131 96% recipients), and Omicron bivalent formulation (mRNA-1273 or BNT162b2, 100%

132 recipients). Baseline SARS-CoV-2 status was determined by virologic (RT-PCR)
133 and/or serologic (anti-nucleocapsid binding antibody) evidence of SARS-CoV-2
134 infection on or before Day 1. No participants reported a known SARS-CoV-2
135 infection within the past 3 months. In Subprotocol 1, 39 (78.0%) participants were
136 SARS-CoV-2 positive at baseline; the PPIS included 48 (96.0%) participants (two
137 were excluded due to a missing or positive SARS CoV-2 RT-PCR result on Day 29).
138 In Subprotocol 2, 43 (86.0%) participants were SARS-CoV-2 positive at baseline; the
139 PPIS included 49 (98.0%) participants (one was excluded due to a positive or
140 missing SARS CoV-2 RT-PCR result on Day 29).

141 Both vaccines elicited robust increases in nAb responses at Day 29 relative to
142 baseline against matched variants (GMFR, 11.6-11.7) and cross-neutralized all
143 tested JN.1-lineage subvariants not matched to the vaccine (GMFR, mRNA-
144 1273.167: KP.2, 8.1; KP.3.1.1, 10.5; XEC, 12.9; LP.8.1, 10.8; GMFR, mRNA-
145 1273.712: JN.1, 10.8; KP.3.1.1, 12.4; XEC, 12.1; LP.8.1, 14.3; **Figure 1**). The highest
146 titers were measured against JN.1 for both vaccines (GMT: mRNA-1273.167,
147 1670.0; mRNA-1273.712, 2796.4). A reduction in cross-neutralization against
148 recently emergent subvariants of JN.1 (KP.3.1.1, XEC, and LP.8.1) relative to nAb
149 titers measured against the JN.1 reference variant was observed for both JN.1- and
150 KP.2-encoding vaccines, with the greatest reduction measured against KP.3.1.1
151 (**Figure 2**). The KP.2-encoding vaccine (mRNA-1273.712) drove higher nAb
152 responses than the JN.1-encoding vaccine (mRNA-1273.617) against all tested
153 variants (**Figure 2**).

154 No vaccine-related SAEs, AEs leading to study withdrawal, or AESIs were
155 reported following vaccination with mRNA-1273.167 or mRNA-1273.712 through the
156 end of study.

157 **Discussion**

158

159 In this phase 3b/4 study in previously COVID-19 vaccinated adults, the
160 updated monovalent variant mRNA-1273 vaccines encoding the JN.1 (mRNA-
161 1273.167) and KP.2 (mRNA-1273.712) variants induced robust nAb responses
162 against the matched variants and cross-neutralized newly emerged JN.1 subvariants
163 (KP.3.1.1, XEC, and LP.8.1), with a reduction in cross-neutralization observed across
164 all subvariants tested compared with JN.1. No safety concerns were identified over
165 the 1-month follow-up period. While both vaccines induced cross-neutralization in
166 line with the expectation of potent cross-reactivity of the recommended JN.1- and
167 KP.2-encoding vaccines against emerging JN.1-lineage subvariants [5, 10]
168 decreased cross-neutralizing titers were measured against KP.3.1.1, XEC, and
169 LP.8.1 for both vaccines; this suggests that more recently emerged variants have
170 developed some immune escape from responses induced by currently approved
171 COVID-19 vaccine compositions. At Day 29, the KP.2 vaccine (mRNA-1273.712)
172 induced higher nAb responses than the JN.1 vaccine (mRNA-1273.167) against all
173 variants tested, suggesting an advantage in preventing escape. The highest degree
174 of reduction in cross-neutralization was observed for KP.3.1.1, in keeping with recent
175 data reporting increased resistance to serum neutralization of KP.3.1.1 relative to
176 XEC in KP.2-encoding vaccine recipients [12]. While the drop in cross-neutralization
177 after the JN.1-encoding and KP.2-encoding vaccines against the JN.1 reference
178 variant in this study ranged between 1.5 and 3.4 for all tested variants, it was lower
179 than that previously reported against JN.1 (~5.8-fold reduction) after booster
180 vaccination with the previously authorized (2023-2024 season) XBB.1.5-encoding
181 mRNA-1273 monovalent vaccine [11]. Together, these data are consistent with
182 recent reports of cross-neutralization induced by KP.2 monovalent boosters against

183 JN.1 subvariants, including KP.3.1.1 and XEC, along with observations of reduced
184 neutralization against these subvariants relative to JN.1 or KP.2 [13, 14]. Similar
185 neutralization performance was reported for the JN.1-encoding mRNA booster
186 vaccine among healthcare workers; the highest neutralization was measured against
187 JN.1, with 1.9- and 2.9-fold lower titers measured against KP.3.1.1 and XEC,
188 respectively [15].

189 The limitations of this study include a small sample size and the lack of
190 durability assessments of nAb responses over multiple time points. In addition,
191 higher baseline titers in the KP.2 vaccine arm might have contributed to the higher
192 nAb titers and fold-rises observed at Day 29, although fold-rises for KP.2, KP.3.1.1,
193 and LP.8.1 were greater in the KP.2 subprotocol despite higher baseline titers.
194 Notably, participant enrollment in the JN.1 and KP.2 vaccine arms was not
195 randomized, and, therefore, comparisons should be made with caution.

196 In conclusion, the JN.1- and KP.2-encoding monovalent mRNA-1273 vaccines
197 elicited robust neutralizing antibody responses against matched variants and cross-
198 neutralized currently circulating JN.1 subvariants KP.3.1.1, XEC, and LP.8.1, with a
199 reduction in cross-neutralization observed against all subvariants tested. No safety
200 concerns were identified.

## Footnotes

These data were previously presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), April 11-15, 2025, Vienna, Austria.

**Acknowledgments.** Medical writing and editorial assistance were provided by Anja Varjačić, PhD, of MEDiSTRAVA in accordance with Good Publication Practice (GPP 2022) guidelines, funded by Moderna, Inc., and under the direction of the authors.

**Author contributions.** A.L.F., B.G., D.K.E., A.N., S.H., X.C., E.d.W., V.U., F.P., R.D., and S.C. conceived and planned the study. A.L.F., B.G., A.N., K.J., S.H., E.d.W., V.U., R.D., and D.C.M. collected the data. A.L.F., B.G., D.K.E., A.N., S.H., X.C., E.d.W., V.U., R.D., D.C.M., and S.C. contributed to data analysis and interpretation. All authors contributed to drafting of the manuscript and contributed to the critical revision of the manuscript for important intellectual content. All authors met the authorship criteria and approved the publication.

**Financial support.** The study was supported by Moderna, Inc.

**Potential conflicts of interest.** A.L. F., B.G., D.K.E., A.N., S.H., X.C., E.D.W., V.U., F.P., R.D., and S.C., are employees of Moderna, Inc., and may hold stock/stock options in the company. K.J. is an employee of CenExel and holds stock in the company. D.C.M. reports laboratory funding from Moderna, Inc.

**Data availability statement**. As the trial is ongoing, access to patient-level data presented in the article and supporting clinical documents by qualified external researchers who provide methodologically sound scientific proposals may be available upon reasonable request for products or indications that have been approved by regulators in the relevant markets and subject to review from 24 months

after study completion. Such requests can be made to Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142 USA << data_sharing@modernatx.com>>. A materials transfer and/or data access agreement with the sponsor will be required for accessing shared data. All other relevant data are presented in the paper.

## References


1. World Health Organization. Updated Risk Evaluation of JN.1 09 February 2024. Available at: https://cdn.who.int/media/docs/default-source/documents/health-topics/sars/jn.1-9-february-2024.pdf. Accessed December 12 2024.
2. Li L, Shi K, Gu Y, et al. Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants. Structure **2024**; 32:1055-67.e6.
3. World Health Organization. WHO COVID-19 dashboard. Available at: https://data.who.int/dashboards/covid19/variants. Accessed March 4 2025.
4. Kaku Y, Okumura K, Kawakubo S, et al. Virological characteristics of the SARS-CoV-2 XEC variant. Lancet Infect Dis **2024**; 24:e736.
5. World Health Organization. Initial Risk Evaluation of LP.8.1 03 February 2025. Available at: https://www.who.int/publications/m/item/risk-evaluation-for-sars-cov-2-variant-under-monitoring-lp81. Accessed March 4 2025.
6. Liu J, Yu Y, Yang S, et al. Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1. Lancet Infect Dis **2025**; 25:e128-30.
7. Centers for Disease Control and Prevention. COVID Data Tracker. Available at: https://covid.cdc.gov/covid-data-tracker/#variant-summary. Accessed April 11 2025.
8. World Health Organization. Statement on the Antigen Composition of COVID-19 Vaccines. Available at: https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines. Accessed March 4 2025.
9. Food and Drug Administration. FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently. Accessed March 4 2025.
10. Lee DW, Nasir A, Elbashir S, et al. mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice. Vaccine **2025**; 54:126961.
11. Chalkias S, McGhee N, Whatley JL, et al. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines. J Infect Dis **2024**; 230:e279-86.
12. Wang Q, Guo Y, Mellis IA, et al. Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC. bioRxiv **2024**:2024.11.17.624037.
13. Suthar MS, Manning KE, Ellis ML, et al. The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant. Lancet Infect Dis **2025**; 25:e122-3.
14. Wang Q, Mellis IA, Wu M, et al. KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2. Lancet Infect Dis **2025**; 25:e133-4.
15. Arora P, Happle C, Kempf A, et al. Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC. Lancet Infect Dis **2024**; 24:e732-3.

274 **Figure Legends**

275

276 **Figure 1**. Neutralizing antibody responses (GMT and GMFR) elicited by mRNA-
277 1273.167 (JN.1-encoding vaccine) and mRNA-1273.712 (KP.2-encoding vaccine)
278 against the vaccine-matched variants (JN.1, KP.2) and newly emerged subvariants
279 (KP.3.1.1, XEC, LP.8.1), per-protocol immunogenicity set.
280 The GMT (Day 1 and Day 29) with the corresponding GMFR (Day 29 relative to Day
281 1) are shown. The per-protocol immunogenicity set included participants who
282 received the planned study intervention, had negative RT-PCR tests at baseline (Day
283 1) and Day 29, and had no major protocol deviations that impacted the key data. The
284 boundary of boxes represents the 25th (bottom) and 75th (top) percentiles of the
285 GMT. The solid line inside the box represents the median (50th percentile) of the
286 GMT. The dashed line inside the box represents the GMT. Whiskers (vertical lines)
287 represent the lowest and highest data points within 1.5 of the interquartile range.
288 The LLOQ is presented using a grey dashed line. The LOD is presented using a
289 brown dashed line.
290 Abbreviations: GMFR, geometric mean fold rise; GMT, geometric mean titer;
291 $ID_{50}$, 50% inhibitory dilution; LLOQ, lower limit of quantification; LOD, limit of
292 detection; RT-PCR, reverse transcription polymerase chain reaction.

293

294

295 **Figure 2**. Geometric mean fold-drop in variant-specific neutralizing antibody
296 responses at Day 29 after mRNA-1273.167 (JN.1-encoding vaccine) and mRNA-
297 1273.712 (KP.2-encoding vaccine), per-protocol immunogenicity set.
298 The LLOQ is presented using a grey dashed line. The LOD is presented using a
299 brown dashed line.
300 Annotated fold change indicates fold-drop compared with the reference variant JN.1.
301 Abbreviations: LLOQ, lower limit of quantification; LOD, limit of detection.
302
303
304

305 **Figure Alt Text**

306 **Figure 1**: Graphs showing neutralizing antibody responses against vaccine-matched
307 variants and newly emerged variants at baseline and Day 29 after JN.1- and KP.2-
308 encoding mRNA-1273.712 vaccines, illustrated with boxplots and individual data
309 points.

310 **Figure 2**: Graphs comparing geometric mean fold-drop in variant-specific
311 neutralizing antibody responses at Day 29 after JN.1- and KP.2-encoding mRNA-
312 1273.712 vaccines, illustrated with bars and individual data points.

**Figure 1**. Neutralizing antibody responses elicited by mRNA-1273.167 (JN.1 vaccine) and mRNA-1273.712 (KP.2 vaccine) against the vaccine-matched variants (JN.1, KP.2) and newly emerged variants (KP.3.1.1, XEC, LP.8.1), per-protocol immunogenicity set.



**Figure 2**. Geometric mean fold-drop in variant-specific neutralizing antibody responses at Day 29 after mRNA-1273.167 (JN.1 vaccine) and mRNA-1273.712 (KP.2 vaccine), per-protocol immunogenicity set.